217 related articles for article (PubMed ID: 15998666)
21. Efalizumab.
Talamonti M; Spallone G; Di Stefani A; Costanzo A; Chimenti S
Expert Opin Drug Saf; 2011 Mar; 10(2):239-51. PubMed ID: 21214420
[TBL] [Abstract][Full Text] [Related]
22. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
Papp KA; Miller B; Gordon KB; Caro I; Kwon P; Compton PG; Leonardi CL;
J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S164-70. PubMed ID: 16488338
[TBL] [Abstract][Full Text] [Related]
23. Treatment of moderate to severe plaque psoriasis with concomitant efalizumab and narrow-band ultraviolet B phototherapy.
Kircik LH; Liu C; Goffe BS
J Drugs Dermatol; 2008 Oct; 7(10):947-52. PubMed ID: 19112758
[TBL] [Abstract][Full Text] [Related]
24. Efalizumab: integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis.
Lynde C
J Cutan Med Surg; 2006; 9 Suppl 1():1-3. PubMed ID: 16633863
[TBL] [Abstract][Full Text] [Related]
25. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
Gottlieb AB; Krueger JG; Wittkowski K; Dedrick R; Walicke PA; Garovoy M
Arch Dermatol; 2002 May; 138(5):591-600. PubMed ID: 12020219
[TBL] [Abstract][Full Text] [Related]
26. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.
Leonardi CL; Toth D; Cather JC; Langley RG; Werther W; Compton P; Kwon P; Wetherill G; Curtin F; Menter A
Dermatology; 2006; 213(3):204-14. PubMed ID: 17033169
[TBL] [Abstract][Full Text] [Related]
27. Efalizumab-induced guttate psoriasis. Successful management and re-treatment.
Balato A; La Bella S; Gaudiello F; Balato N
J Dermatolog Treat; 2008; 19(3):182-4. PubMed ID: 18569275
[TBL] [Abstract][Full Text] [Related]
28. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.
Scanlon JV; Exter BP; Steinberg M; Jarvis CI
Ann Pharmacother; 2009 Sep; 43(9):1456-65. PubMed ID: 19671802
[TBL] [Abstract][Full Text] [Related]
29. Current concepts and review of efalizumab in the treatment of psoriasis.
Leonardi CL
Dermatol Clin; 2004 Oct; 22(4):427-35, ix. PubMed ID: 15450338
[TBL] [Abstract][Full Text] [Related]
30. Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study.
Tsai TF; Liu MT; Liao YH; Licu D
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):345-52. PubMed ID: 18005021
[TBL] [Abstract][Full Text] [Related]
31. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.
Langley RG; Carey WP; Rafal ES; Tyring SK; Caro I; Wang X; Wetherill G; Gordon KB
Clin Ther; 2005 Sep; 27(9):1317-28. PubMed ID: 16291408
[TBL] [Abstract][Full Text] [Related]
32. Efalizumab in moderate-to-severe plaque psoriasis: a retrospective case series analysis from clinical practice.
Cassano N; Mastrandrea V; Buquicchio R; Miracapillo A; Loconsole F; Filotico R; Vena GA
J Biol Regul Homeost Agents; 2008; 22(3):185-93. PubMed ID: 18842172
[TBL] [Abstract][Full Text] [Related]
33. Efalizumab: continuous therapy for chronic psoriasis.
Cather JC; Menter A
Expert Opin Biol Ther; 2005 Mar; 5(3):393-403. PubMed ID: 15833076
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.
Costanzo A; Talamonti M; Spallone G; Botti E; Chimenti MS; Papoutsaki M; Chimenti S
Dermatology; 2009; 218(2):146-50. PubMed ID: 18971577
[TBL] [Abstract][Full Text] [Related]
35. Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II.
Papp KA; Camisa C; Stone SP; Caro I; Wang X; Compton P; Walicke PA; Gottlieb AB
J Cutan Med Surg; 2005 Dec; 9(6):313-23. PubMed ID: 16699903
[TBL] [Abstract][Full Text] [Related]
36. Exacerbation of psoriasis under efalizumab therapy.
Rallis E; Verros C; Karanikola E; Valaskatzi A; Papaconstantis M
J Cutan Med Surg; 2009; 13(2):106-9. PubMed ID: 19298780
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of subcutaneously administered efalizumab in adults with moderate-to-severe hand and foot psoriasis: an open-label study.
Varma R; Cafardi JA; Cantrell W; Elmets C
Am J Clin Dermatol; 2008; 9(2):105-9. PubMed ID: 18284264
[TBL] [Abstract][Full Text] [Related]
38. [Efalizumab. Long-term treatment of psoriasis].
Prinz JC
Hautarzt; 2005 Sep; 56(9):812-8. PubMed ID: 16096737
[TBL] [Abstract][Full Text] [Related]
39. Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark.
Kragballe K
Br J Dermatol; 2007 Apr; 156 Suppl 2():7-11. PubMed ID: 17371317
[TBL] [Abstract][Full Text] [Related]
40. Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute.
Ferrándiz C; Carrascosa JM
Br J Dermatol; 2007 Apr; 156 Suppl 2():24-9. PubMed ID: 17371320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
